Member Info for RayPointer

I'm throwing my bat into the ring.
I will eat it if the SP hits 20p by close.
I hope this doesn't start a new Coronavirus pandemic.

We would require a video of the actual hat eating and samples of the hat sent to a laboratory confirm it is really a hat and not a Christmas cake

I'm kind of in the middle in this debate.
These 3 trials could be seen as verification of Lindy's T Cell work of 30 years of more.
There is commonality between the three trials that comprises the carful identification of targets, the painstaking work to prove that there is no likely toxicity, the high avidity of the T Cells, the strong clonal expansion, and evidence of the creation of memory T Cells.
Of course, we also do see differences in Moditope and Immunobody. Moditope needs an adjuvant and Immunobody does not. Moidtope avtivates cytotoxic CD4 T Cells whereas Immunobody goes down the more normal route of CD8 killers and CD4 helpers.
IMO Lindy is a great scientist and perhaps some would agree. But just how great we may be about to see. The very greatest of scientists are quite often right.
One thing is clear, Lindy has strong ideas on how to beat cancer, and has not changed her basic approach for a long time.

Anyone care to join me in the happy clappy centre-left party :-)

Since the SP has not reacted, I would assume one is a buy and the other a sell.

Since the SP has not reacted, I would assume one is a buy and the other a sell.

I won't post all the names of the scientists that have endorsed Lindy's work since I don't want LSE to run out of disk storage space. :-)

16 minutes 20 seconds into the video Sarah starts talking about SCIB1.
Also, elsewhere in the video, she mentions Poulem on at least 2 occasions. I assume she is referring to Poulem Patel, chief investigator for the SCIB1 trial.

Hey , that's a good spot Johnny.
That makes 5 centres now recruiting.

Velindre University NHS Trust Recruiting
Cardiff, United Kingdom
Contact: Satish Kumar, MD
Principal Investigator: Satish Kumar, MD

East and North Hertfordshire NHS Trust Recruiting
Northwood, United Kingdom
Contact: Heather Shaw, MD
Principal Investigator: Heather Shaw, MD

Nottingham University Hospitals NHS Trust Recruiting
Nottingham, United Kingdom
Contact: Poulam M Patel, MD
Principal Investigator: Poulam M Patel, MD

Oxford University Hospital NHS Foundation Trust Recruiting
Oxford, United Kingdom
Contact: Miranda Payne, MD
Principal Investigator: Miranda Payne, MD

Sheffield Teaching Hospital NHS Foundation Trust Recruiting
Sheffield, United Kingdom
Contact: Sarah Danson, MD
Principal Investigator: Sarah Danson, MD

Quiet day today.
What time do the patients wake up?

Maybe by modi1 trial patients :-)

We do have our own Superwoman :-)

No apology necessary, Bermuda :-)

An article about this particular protein

https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glucose-regulated-protein

Here are some important sentences

"In cancer, up-regulation of GRP78 is widely observed and associated with aggressive growth and invasiveness."

"The discovery that GRP78 is preferentially expressed on the surface of cancer cells, but not normal organs in vivo, further opens a promising strategy for tumor specific targeting."

"However, the mechanisms for stress-induced translocation of GRP78 to the cell surface are just emerging. "

It looks like Lindy's team have detected citrullination is occurring under stress making it a target for Moditope.

SCIB1 was granted orphan status by the FDA a long time ago.

The avidimab poster is all about improving the affinity of SEA-CD40

This is a mAb developed by creative biolabs and is currently at phase 1 trials

https://adcc.creative-biolabs.com/sea-cd40.htm

I wonder if creative biolabs is one of Scancell's collaborators. It might explain why this particular mAb was chosen to demonstrate the effect of Avidimab.

Probably due to customers converting to cash I would say.

Hi Ivy
Yes, its interesting times.
Lindy claimed that Covidity's pre-clinical data was superior to that of the approved vaccines. Of course, that does not mean that human results will also be superior.
The only pointer we have is that SCIB1 trial results surpassed Lindy's best expectations, and Covidity is based on SCIB1 but targeting different epitopes of course. Covidity also has the extra boost given by Avidimab.
I think you are right in that companies that missed out on the first wave of vaccines may be the most interested parties, plus CEPI of course. The current vaccine providers may well be content to tweak their vaccines each year as new variants become dominant.
Going back to Avidimab, it will also be interesting to see the new poster. If Lindy can also prove the effect that the inclusion of Avidimab had on Covidity, then this evidence coupled with the extra pre-clinical work on Avidimab may lead to deals for Avidimab being applied to existing mAbs. Even more interesting.

Ivy
Lindy did mention the possibility of an Immumobody deal in answer to a question on a Covidity deal.
It's not to be ruled out. We just don't know what discussions, if any, have already taken place.
Certainly CEPI have expressed interest in platform technology.

The way I see it is that, yes, more data is now available.
The scientists employed by our collaborators will analyse the data and make recommendations to their management.
So, the burning question is "by how much has the data improved?"
Perhaps we can have our own shot at guessing that when we see the new posters and compare to the previous posters that I believe were presented at the Paris conference some time ago.

chester, I waited for your reply first :-)